1,1'-Carbonyldiimidazole → 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester

HRID 1991312

Reaktionsgleichung

Reaktionsgleichung von HRID 1991312
C1N=CN([C:6](N2C=NC=C2)=[O:7])C=1.[CH2:13]([O:15][C:16](=[O:35])[C@H:17]([OH:34])[CH2:18][NH:19][C:20]1[CH:25]=[CH:24][C:23]([N:26]2[CH:31]=[CH:30][C:29](=[O:32])[CH2:28][CH2:27]2)=[C:22]([F:33])[CH:21]=1)[CH3:14]>C(#N)C>[CH2:13]([O:15][C:16]([CH:17]1[O:34][C:6](=[O:7])[N:19]([C:20]2[CH:25]=[CH:24][C:23]([N:26]3[CH:27]=[CH:28][C:29](=[O:32])[CH2:30][CH2:31]3)=[C:22]([F:33])[CH:21]=2)[CH2:18]1)=[O:35])[CH3:14]

Komponenten

4

Edukt 2

HCID 682631,1'-CarbonyldiimidazoleHCID 684871023-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenylamino]-2(R)-hydroxypropionic acid ethyl ester

Produkt 1

HCID 684890643-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6342AcetonitrileLösungsmittel

Versuchsvorschrift

CDI (162.0 mg, 1.0 mmol) is added with stirring to a solution of 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenylamino]-2(R)-hydroxypropionic acid ethyl ester (Step 5, 146.0 mg, 0.45 mmol) in acetonitrile (4.0 mL), and the mixture is stirred at room temperature overnight. Solvent is removed under vacuum, and the residue partitioned between EtOAc (30 mL) and aq. 3% citric acid (30 mL). The aqueous layer is extracted with EtOAc (2×30 mL), and the combined organic layers are washed with water and saline and dried (MgSO4). EtOAc is removed under vacuum to afford the crude 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester which is used in the next step w/o further purification (MS (m/z): 349 [M+H]+). The ester intermediate is taken up in 2M methanolic ammonia (8.0 mL, 16.0 mmol), and the resulting solution heated in a closed vial at 60° C. for 1 h. Volatiles are removed under vacuum, and the crude material purified by silica gel chromatography (eluent: 2% MeOH in CH2Cl2) to afford the title compound (55.0 mg, 38% for two steps) as white crystals, MS for C15H14FN3O4 m/z 320 (M+H)+; 1H NMR (CD3CN): δ 2.51 (m, 2 H), 3.89 (m, 2 H), 4.05 (m, 1 H), 4.24 (dd, 1 H), 4.97 (m, 1 H), 5.03 (d, 1 H), 6.18 (br. s, 1 H), 6.72 (br. s, 1 H), 7.20-7.40 (m, 3 H), 7.57 (d, 1 H).

Aufarbeitung

  1. customSolvent is removed under vacuum
  2. customthe residue partitioned between EtOAc (30 mL) and aq. 3% citric acid (30 mL)
  3. extractionThe aqueous layer is extracted with EtOAc (2×30 mL)
  4. washthe combined organic layers are washed with water and saline
  5. dry with materialdried (MgSO4)
  6. customEtOAc is removed under vacuum

Quellen und Nachweise

ORD-Eintrag
ord-c01938d669ce4a02836ad8a7a36c7fbc
Quelldatensatz
uspto-grants-2010_01
Patentnummer
US07645781B2

Verknüpfte Notizen

Wird geladen…